https://en.bioecon.ru/companies/roche/Recent content in Roche on BioeconHugoen-USWed, 29 Jul 2026 10:12:38 +0700https://en.bioecon.ru/technology/bispecific-antibodies/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/bispecific-antibodies/Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient’s own T cells to a tumour cell — delivered off-the-shelf as approved drugs across lymphoma and myeloma by Roche, Janssen, Regeneron, AbbVie/Genmab and BeiGene.https://en.bioecon.ru/technology/diagnostics-biosensors/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/diagnostics-biosensors/Advanced analytical devices detecting biological markers to enable rapid, precise disease identification and monitoring.https://en.bioecon.ru/technology/biologics/Thu, 18 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biologics/Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at 2–10 g/L titers.